asco 2018 - potential showdown of two positive trials? keynote 407 and impower 131
Published 5 years ago • 195 plays • Length 12:26Download video MP4
Download video MP3
Similar videos
-
11:15
asco 2018 - keynote 042 - keytruda as a single agent compared to doublet chemotherapy for nsclc
-
11:29
asco 2018 keynote189 - cisplatin or carboplatin with alimta & keytruda - practice changing approach?
-
4:26
asco 2018 - dream study - chemo with imfinzi (durvalumab) for mesothelioma
-
9:40
asco 2018 - checkmate 227 - combinations of nivolumab and ipilimumab, or nivolumab and and chemo
-
9:21
asco lung cancer roundtable - nsclc - new potential treatments for met and ret positive nsclc
-
3:34
asco 2018 - keynote 158 - keytruda in previously treated, now relapsing patients with sclc
-
2:52
asco 2018 - combining metformin with standard egfr therapy - is the jury still out
-
6:27
asco 2018 - tarceva combined with carboplatin & alimta - given upfront - affect pace of disease?
-
7:35
asco 2018 - will taking mod to high dose steroids affect lung cancer pts on immunotherapy?
-
2:00
keynote 671: perioperative pembrolizumab for nsclc - onctalk lung 2023
-
11:48
asco lung cancer roundtable - nsclc trial updates: checkmate 9la opdivo and yervoy with chemo vs
-
14:00
asco 2021 lung recap: impower010: atezolizumab after chemo in non-small cell lung cancer
-
10:19
gracecast- asco lung 2020- new potential treatments for met and ret positive nsclc capmatinib-tabrec
-
9:11
asco 2018 - tarceva or tarceva with avastin as 1st line for egfr pos. nsclc vs. tagrisso or vizimpro
-
10:08
asco/esmo 2020 - head and neck cancer updates - javelin100 trial update
-
9:36
gracecast-021_lung-cancer_stage iiia management options
-
5:11
gracecast-114_lung-cancer_asco 2012 lc highlights: dr. neal on mek inhibitor selumetinib in nsclc
-
6:00
the adaura trial: 2023 updates - targeted therapies in lung cancer 2023